The finding that in all cases of neoadjuvant TKI treated patient's RCC specimens IL-6 was highly expressed, whereas in patients without TKI treatment no or only very low IL-6 expression was detectable, suggests that the cell line 786-O reflects the situation in vivo and we therefore used it for all further investigations. This evidence concerns the gene IL6 and renal cell carcinoma.